In a 187-patient Phase 2b study in systemic lupus erythematosus, orelabrutinib 75 mg once daily achieved a 57.1% SRI-4 response at week 48 versus 34.4% on placebo (p<0.05), meeting the primary endpoint. The 75 mg arm also showed statistically significant gains on SRI-6 and BICLA, with a dose-response trend relative to 50 mg. The drug was described as well tolerated, with no new safety signals reported. The immediate development is twofold: InnoCare, which ran the study, has secured China CDE approval to initiate a registrational Phase 3 program in SLE, and Zenas—InnoCare’s partner—has clarified its rights posture following an October 2025 license. Zenas holds global rights in multiple sclerosis and ex-Greater China/SE Asia rights across non-oncology indications, while InnoCare retains oncology. In parallel, Zenas is already running a Phase 3 program in primary progressive MS with a secondary progressive MS Phase 3 slated to start in early 2026, positioning orelabrutinib as a cross-indication, CNS-penetrant BTK platform if data hold. Strategically, InnoCare’s rapid pivot to registration in China leverages a clean 48-week signal across both SRI- and BICLA-based endpoints, a pattern regulators have been increasingly receptive to when composites are consistent and background therapy is controlled. For Zenas, the readout reinforces the broader thesis that highly selective, CNS-penetrant BTK inhibition can extend beyond MS into systemic autoimmunity, and it provides dose-selection clarity, with 75 mg QD emerging as the likely registrational dose. The oral administration and potential to avoid infusion infrastructure give the molecule a pragmatic edge against biologic incumbents in SLE—assuming steroid-sparing effects and organ-domain robustness can be demonstrated in Phase 3. Operationally, the China Phase 3 will require lupus-experienced sites with established training on BICLA adjudication and standardized steroid taper protocols to meet modern regulatory expectations. CROs with rheumatology and composite-endpoint expertise should see near-term demand. For sponsors and regulators outside China, the result reopens the question of BTK’s role in SLE after a mixed class history and sets the stage for ex-China development that will need to satisfy FDA and EMA preferences on endpoint hierarchy, background therapy stability, and validation across organ systems. Vendors supporting central review, flare capture, and complement/anti-dsDNA monitoring are likely to be integral to data integrity and subgroup analyses. The next set of choices will be decisive. InnoCare’s registrational design—breadth of organ involvement, renal subset strategy, glucocorticoid taper requirements, and flare definitions—will determine how persuasive the dataset is beyond China. For Zenas, whether and when to launch an ex-China SLE program, and how to harmonize dose, endpoints, and CMC with the China program, will influence timelines and global labeling coherence. Durability beyond 48 weeks, steroid-sparing evidence, and a detailed safety profile, including infection, bleeding, and hepatic signals typical for the class, remain the critical risk variables. On the MS side, read-through from progressive MS to systemic disease biology is not guaranteed; nonetheless, a positive SLE signal supports the platform narrative and could ease site engagement and funding prioritization into 2026. Watch for Phase 3 protocol specifics from China, clarity on ex-China SLE plans, and interim MS milestones that collectively test whether a CNS-penetrant BTK inhibitor can credibly compete as an oral option across two complex autoimmune franchises.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
